Omalizumab.

Abstract

* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic patients treated with omalizumab. * Omalizumab was also effective in the treatment of children with allergic asthma demonstrating improvements in health-related quality-of-life and significant dosage reductions of inhaled corticosteroids. * Administration of omalizumab to patients with allergic rhinitis resulted in a rapid dose-dependent suppression of serum free IgE levels. * Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergic rhinitis. Antihistamine requirements were also significantly reduced following treatment. * Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria.

• Authors: S Easthope, B Jarvis
• Journal: Drugs (Drugs) Vol. 61 Issue 2 Pg. 253-60; discussion 261 ( 2001) ISSN: 0012-6667 [Print] New Zealand
• PMID: 11270941 (Publication Type: Journal Article)

Chemical References

• Anti-Allergic Agents
• Anti-Asthmatic Agents
• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Histamine Antagonists
• Omalizumab
• Immunoglobulin E

Topics

• Anti-Allergic Agents (pharmacology, therapeutic use)
• Anti-Asthmatic Agents (pharmacology, therapeutic use)
• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Asthma (drug therapy, immunology, pathology)
• Histamine Antagonists (therapeutic use)
• Histamine Release (drug effects)
• Humans
• Immunoglobulin E (blood, immunology)
• Omalizumab
• Rhinitis, Allergic, Seasonal (immunology)